Immunotherapy in Renal Cell Carcinoma The Future Is Now - Université de Rennes Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2020

Immunotherapy in Renal Cell Carcinoma The Future Is Now


Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.
Fichier principal
Vignette du fichier
ijms-21-02532.pdf (962.22 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-02565718 , version 1 (17-07-2020)





Antoine Deleuze, Judikaël Saout, Frédéric Dugay, Benoit Peyronnet, Romain Mathieu, et al.. Immunotherapy in Renal Cell Carcinoma The Future Is Now. International Journal of Molecular Sciences, 2020, 21 (7), pp.2532. ⟨10.3390/ijms21072532⟩. ⟨hal-02565718⟩
54 View
95 Download



Gmail Facebook X LinkedIn More